Abstract
RATIONALE: In a recent US survey of 207 perennial allergic rhinitis (PAR) patients, 20.6% of patients reported having mild PAR and 58.8% reported having moderate PAR. We examined the efficacy of mometasone furoate nasal spray (MFNS) in subjects with mild-to-moderate PAR.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
